724.38
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $724.38, with a volume of 590.94K.
It is up +0.67% in the last 24 hours and up +0.03% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$719.57
Open:
$719.57
24h Volume:
590.94K
Relative Volume:
0.60
Market Cap:
$88.11B
Revenue:
$359.05B
Net Income/Loss:
$3.30B
P/E Ratio:
28.04
EPS:
25.83
Net Cash Flow:
$5.23B
1W Performance:
+2.77%
1M Performance:
+0.03%
6M Performance:
+28.71%
1Y Performance:
+21.25%
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MCK
Mckesson Corporation
|
724.38 | 88.11B | 359.05B | 3.30B | 5.23B | 25.83 |
![]()
COR
Cencora Inc
|
293.20 | 55.09B | 310.23B | 1.69B | 3.58B | 8.62 |
![]()
CAH
Cardinal Health Inc
|
164.91 | 36.54B | 222.29B | 1.56B | 2.44B | 6.41 |
![]()
HSIC
Henry Schein Inc
|
70.16 | 8.92B | 12.50B | 314.00M | 421.00M | 2.44 |
![]()
OMI
Owens Minor Inc
|
7.54 | 623.64M | 10.42B | -38.77M | 323.54M | -0.51 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Resumed | Mizuho | Neutral |
Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Sep-05-24 | Reiterated | Leerink Partners | Outperform |
Aug-08-24 | Reiterated | Mizuho | Neutral |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Jan-03-24 | Initiated | Barclays | Overweight |
Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
Mar-31-23 | Initiated | Citigroup | Buy |
Aug-22-22 | Resumed | Morgan Stanley | Overweight |
Jul-06-22 | Downgrade | Argus | Buy → Hold |
Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-01-22 | Resumed | Credit Suisse | Outperform |
Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
Nov-02-21 | Reiterated | Barclays | Overweight |
Nov-02-21 | Reiterated | BofA Securities | Buy |
Nov-02-21 | Reiterated | Evercore ISI | Outperform |
Nov-02-21 | Reiterated | Jefferies | Buy |
Mar-30-21 | Upgrade | Argus | Hold → Buy |
Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
May-15-20 | Upgrade | UBS | Neutral → Buy |
Apr-23-20 | Resumed | Credit Suisse | Neutral |
Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-12-19 | Initiated | Deutsche Bank | Hold |
Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jul-22-19 | Initiated | Guggenheim | Neutral |
Jan-17-19 | Initiated | UBS | Neutral |
Oct-26-18 | Reiterated | Barclays | Equal Weight |
Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
Mar-08-18 | Initiated | Barclays | Equal Weight |
Feb-27-18 | Resumed | BofA/Merrill | Buy |
Feb-02-18 | Reiterated | Mizuho | Neutral |
Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
Why McKesson (MCK) is a Top Growth Stock for the Long-Term - Yahoo Finance
Morgan Stanley Hikes McKesson (MCK) Price Target on Earnings Growth Prospects - Insider Monkey
Wells Fargo Affirms McKesson (MCK) Equal Weight Rating and $766 Price Target - Insider Monkey
Leerink Partners Remains Bullish on McKesson Corporation (MCK), Retains a $785 Price Target - Insider Monkey
Here's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today - Benzinga
McKesson (MCK) Rises Higher Than Market: Key Facts - Yahoo Finance
Stan Wong's Top Picks: iShares Silver Bullion ETF, McKesson & Nvidia - BNN Bloomberg
McKesson (NYSE:MCK) Price Target Raised to $770.00 at Morgan Stanley - Defense World
McKesson Adjusts Earnings Outlook Amid Pharma Growth - Finimize
McKesson Boosts Fiscal 2026 EPS Guidance on Operational Strength, Morgan Stanley Says - marketscreener.com
McKesson (MCK) Price Target Raised by Morgan Stanley | MCK Stock News - GuruFocus
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know - Yahoo Finance
McKesson to Host Investor Day on September 23, 2025 - BioSpace
McKesson to Host Investor Day on September 23, 2025 | MCK Stock News - GuruFocus
McKesson (MCK) Revises Earnings Projections for Fiscal Year 2026 - GuruFocus
McKesson (MCK) Price Target Raised by Morgan Stanley to $770 | M - GuruFocus
McKesson price target raised to $770 from $745 at Morgan Stanley - TipRanks
McKesson (MCK) Revises Earnings Projections for Fiscal Year 2026 | MCK Stock News - GuruFocus
McKesson (MCK) Price Target Raised by Morgan Stanley to $770 | MCK Stock News - GuruFocus
Those who invested in McKesson (NYSE:MCK) five years ago are up 366% - simplywall.st
McKesson stock price target raised at Morgan Stanley on growth outlook - Investing.com India
Global Clinical Workflow Management Software Market Projected to Reach USD USD 40,243 million by 2030., Growing at a 22.97% CAGR: MarkNtel AdvisorsLeading key players (GE Healthcare, Oracle Health, Allscripts Healthcare Solutions, Siemens Heal - The Malaysian Reserve
McKesson Corporation (MCK) Updates Fiscal Year 2026 Financial Outlook - GuruFocus
McKesson CEO Tyler Brian S. sells shares for $13.67 million By Investing.com - Investing.com South Africa
McKesson CEO Tyler Brian S. sells shares for $13.67 million - Investing.com
McKesson Stock: Is Wall Street Bullish or Bearish? - MSN
Mckesson Says Executives To Meet With Investors And AnalystsSEC Filing - marketscreener.com
McKesson Updates Fiscal Year 2026 Financial Outlook - TipRanks
McKesson Raises FY Earnings Outlook - MarketWatch
McKesson leads the charge in revolutionizing precision oncology in community practices - Endpoints News
McKesson Stock: Is MCK Outperforming the Healthcare Sector? - MSN
McKesson Corporation Acquires Florida Cancer Specialists Core Ventures to Expand Community-Based Oncology Care - geneonline.com
Wells Fargo Raises McKesson (MCK) Price Target, Maintains Equal Weight Rating - MSN
Mizuho Adjusts Price Target on McKesson to $735 From $690, Maintains Neutral Rating - marketscreener.com
3 Reasons We Love McKesson (MCK) - FinancialContent
McKesson Corporation Acquires Florida Cancer Specialists to Expand Community-Based Oncology Care - geneonline.com
McKesson Stock: Is MCK Outperforming The Healthcare Sector? - Barchart.com
McKesson completes acquisition of Core Ventures - Drug Store News
Wells Fargo & Company Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price - Defense World
McKesson acquires majority stake in Core Ventures By Investing.com - Investing.com South Africa
McKesson Corporation (MCK) Finalizes Purchase of Core Ventures - Insider Monkey
McKesson (MCK): Wells Fargo Raises Price Target to $766 | MCK St - GuruFocus
McKesson Acquires 70% Stake In Core Ventures To Boost Community Oncology Access - Nasdaq
McKesson completes control acquisition of cancer care clinics for $2.5B - The Business Journals
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
McKesson Finalizes Acquisition of 70% Stake in Core Ventures for $2.49 Billion - marketscreener.com
McKesson to spin off Medical-Surgical Solutions segment, focus on high-growth oncology and biopharma markets - HME News
McKesson Acquires Core Ventures - citybiz
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):